Log in

Relevant bibliographies by topics / Lumefantrina / Journal articles

To see the other types of publications on this topic, follow the link: Lumefantrina.

Journal articles on the topic 'Lumefantrina'

Author: Grafiati

Published: 9 September 2021

Last updated: 29 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Lumefantrina.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Gonçalves, Bruna Vaz da Silva, Isis Regina Barberini, and Silvana Krychak Furtado. "Panorama global acerca da eficácia de medicamentos antimaláricos para o tratamento de p. falciparum e p. vivax no período de 2010 a 2018." Scire Salutis 12, no. 2 (2022): 10–18. http://dx.doi.org/10.6008/cbpc2236-9600.2022.002.0002.

Full text

Abstract:

Há um amplo consenso de que proteger a eficácia dos medicamentos antimaláricos é uma prioridade de saúde global. O trabalho foi desenvolvido por meio do levantamento de um total de 925 estudos de eficácia terapêutica conduzidos e documentados pela OMS acerca da eficácia de antimaláricos aplicados às espécies de plasmódio supracitados entre o período de 2010 a 2018. O número de estudos sobre a eficácia terapêutica para antimaláricos aplicados para P. falciparum resultam em artemeter-lumefantrina que inclui 317 estudos realizados em 50 países. Artesunato-amodiaquina incluiu 122 estudos em 26 paí

APA, Harvard, Vancouver, ISO, and other styles

2

Freitas-Marques, Maria Betânia de, Wagner da Nova Mussel1, Maria Irene Yoshida, Christian Fernandes, Tércio Assunção Pedros, and Pedro Henrique Reis da Silva. "Interações químicas entre monômero e molécula molde em polímeros com impressão molecular, o EGDMA: 2-VP (4: 1) - estudo de caso MIP lumefantrina." Journal of Experimental Techniques and Instrumentation 4, no. 04 (2021): 56–76. http://dx.doi.org/10.30609/jeti.v4i04.14486.

Full text

Abstract:

Molecularly Imprinted Polymers (MIP) are synthetic materials used as a tool to enhance the selectivity in different analytical approaches, such as solid-phase extraction, chromatography, and sensing devices. Knowing the mechanism involved in the interaction between the template and monomer is essential for a further successful application. However, studies on this topic are scarce. This work evaluates the involved mechanisms in the template-monomer interaction for a lumefantrine MIP system, an antimalarial drug. Field-emission gun scanning electron microscopy, thermal analysis, X-ray diffracti

APA, Harvard, Vancouver, ISO, and other styles

3

Lima, Agostinho Viana, and Fernando Mitano. "Saberes sobre a malária: um estudo qualitativo baseado no Distrito do Lago, Província de Niassa (Moçambique – África)." VITTALLE - Revista de Ciências da Saúde 32, no. 3 (2020): 107–18. http://dx.doi.org/10.14295/vittalle.v32i3.11819.

Full text

Abstract:

Procurou-se compreender o modo como a população do Distrito do Lago (Província de Niassa, Moçambique) percebe, previne e trata a malária. Trata-se de um estudo de cunho qualitativo, centrado na abordagem de modelos explicativos da doença, que contou com a participação de membros de agregados familiares, profissionais de saúde e médicos tradicionais. A coleta de dados aconteceu por meio de entrevistas, orientadas por um roteiro semiestruturado, realizadas nos meses de Setembro e Novembro de 2019 em 8 povoados do Distrito do Lago. Os resultados revelaram um entendimento de que a malária é uma do

APA, Harvard, Vancouver, ISO, and other styles

4

Carmona-Fonseca, Jaime, Olga María Agudelo-García, and Eliana Arango-Flórez. "Eficacia terapéutica y eventos adversos de tratamientos para malaria vivax y malaria falciparum en gestantes en las regiones de Urabá y Alto San Jorge, Colombia, 2008-2011." Revista Colombiana de Obstetricia y Ginecología 64, no. 1 (2013): 27–37. http://dx.doi.org/10.18597/rcog.127.

Full text

Abstract:

Objetivo: evaluar, con el protocolo de la Organización Mundial de la Salud (OMS) de 1998, la respuesta terapéutica antimalárica (RTA) y los eventos adversos (EA) en cuatro esquemas de tratamiento antiplasmodial en gestantes colombianas, con diagnóstico de malaria no complicada por P. vivax o por P. falciparum, según gota gruesa.Materiales y métodos: experimento controlado aleatorizado en paralelo. Se calculó un tamaño muestral de 60 pacientes con P. vivax y 30 con P. falciparum. Se evaluaron cuatro tratamientos: malaria vivax en cualquier trimestre de gestación tratada con cloroquina o con amo

APA, Harvard, Vancouver, ISO, and other styles

5

Cortés Jiménez, Lady Tatiana, Camilo Andrés Rivera Perdomo, Duván Felipe Velandia, Lorena García Agudelo, and Ledmar Jovanny Vargas Rodríguez. "Malaria autóctona: caso clínico." Revista Med 32, no. 1 (2024): 101–6. http://dx.doi.org/10.18359/rmed.7183.

Full text

Abstract:

Introducción: La malaria o paludismo es una infección parasitaria frecuente en las regiones tropicales del mundo, donde anualmente se infectan entre 300 y 500 millones de personas, siendo responsable de 1,5 a 2,7 millones de muertes al año. Hoy en día es considerada un problema de salud pública grave por las condiciones que facilitan la reproducción y transmisión del parásito Plasmodium. Objetivo: El objetivo del manuscrito es presentar el caso de un paciente con malaria autóctona. Caso clínico: Paciente femenina de 33 años, quien consultó por cuadro clínico de doce días de evolución consisten

APA, Harvard, Vancouver, ISO, and other styles

6

Kloprogge, Frank, Rose McGready, Warunee Hanpithakpong, et al. "Lumefantrine and Desbutyl-Lumefantrine Population Pharmacokinetic-Pharmacodynamic Relationships in Pregnant Women with Uncomplicated Plasmodium falciparum Malaria on the Thailand-Myanmar Border." Antimicrobial Agents and Chemotherapy 59, no. 10 (2015): 6375–84. http://dx.doi.org/10.1128/aac.00267-15.

Full text

Abstract:

ABSTRACTArtemether-lumefantrine is the most widely used antimalarial artemisinin-based combination treatment. Recent studies have suggested that day 7 plasma concentrations of the potent metabolite desbutyl-lumefantrine correlate better with treatment outcomes than those of lumefantrine. Low cure rates have been reported in pregnant women with uncomplicated falciparum malaria treated with artemether-lumefantrine in northwest Thailand. A simultaneous pharmacokinetic drug-metabolite model was developed based on dense venous and sparse capillary lumefantrine and desbutyl-lumefantrine plasma sampl

APA, Harvard, Vancouver, ISO, and other styles

7

Wahajuddin, Kanumuri S. R. Raju, Sheelendra P. Singh, and Isha Taneja. "Investigation of the Functional Role of P-Glycoprotein in Limiting the Oral Bioavailability of Lumefantrine." Antimicrobial Agents and Chemotherapy 58, no. 1 (2013): 489–94. http://dx.doi.org/10.1128/aac.01382-13.

Full text

Abstract:

ABSTRACTIn the quest to explore the reason for the low and variable bioavailability of lumefantrine, we investigated the possible role of P-glycoprotein (P-gp) in lumefantrine intestinal absorption. Anin situsingle-pass intestinal perfusion study in rats with the P-gp inhibitor verapamil or quinidine and an ATPase assay with human P-gp membranes indicated that lumefantrine is a substrate of P-gp which limits its intestinal absorption. To confirm these findings, anin vivopharmacokinetic study was performed in rats. The oral administration of verapamil (10 mg/kg of body weight) along with lumefa

APA, Harvard, Vancouver, ISO, and other styles

8

Salman, Sam, Madhu Page-Sharp, Susan Griffin, et al. "Population Pharmacokinetics of Artemether, Lumefantrine, and Their Respective Metabolites in Papua New Guinean Children with Uncomplicated Malaria." Antimicrobial Agents and Chemotherapy 55, no. 11 (2011): 5306–13. http://dx.doi.org/10.1128/aac.05136-11.

Full text

Abstract:

ABSTRACTThere are sparse published data relating to the pharmacokinetic properties of artemether, lumefantrine, and their active metabolites in children, especially desbutyl-lumefantrine. We studied 13 Papua New Guinean children aged 5 to 10 years with uncomplicated malaria who received the six recommended doses of artemether (1.7 mg/kg of body weight) plus lumefantrine (10 mg/kg), given with fat over 3 days. Intensive blood sampling was carried out over 42 days. Plasma artemether, dihydroartemisinin, lumefantrine, and desbutyl-lumefantrine were assayed using liquid chromatography-mass spectro

APA, Harvard, Vancouver, ISO, and other styles

9

Parikh, Sunil, Fatai Fehintola, Liusheng Huang, et al. "Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy." Antimicrobial Agents and Chemotherapy 59, no. 12 (2015): 7852–56. http://dx.doi.org/10.1128/aac.01153-15.

Full text

Abstract:

ABSTRACTCoadministration of nevirapine-based antiretroviral therapy (ART) and artemether-lumefantrine is reported to result in variable changes in lumefantrine exposure. We conducted an intensive pharmacokinetic study with 11 HIV-infected adults who were receiving artemether-lumefantrine plus nevirapine-based ART, and we compared the results with those for 16 HIV-negative adult historical controls. Exposure to artemether and lumefantrine was significantly lower and dihydroartemisinin exposure was unchanged in subjects receiving nevirapine-based ART, compared with controls. Nevirapine exposure

APA, Harvard, Vancouver, ISO, and other styles

10

Abolaji, AO, OA Adesanoye, I. Awogbindin, and EO Farombi. "Endocrine disruption and oxidative stress implications of artemether–lumefantrine combination therapy in the ovary and uterus of rats." Human & Experimental Toxicology 35, no. 11 (2016): 1173–82. http://dx.doi.org/10.1177/0960327115626580.

Full text

Abstract:

In the current study, we evaluated the endocrine disruption effect and oxidative stress implication of therapeutic dose of artemether–lumefantrine combination therapy on the ovary and uterus of rats. In this respect, female rats were divided into four groups: animals were per orally treated with tween 80 (control), artemether (4 mg kg−1 body weight), lumefantrine (24 mg kg−1 body weight) and artemether–lumefantrine (artemether, 4 mg kg−1 body weight and lumefantrine, 24 mg kg−1 body weight). We found that therapeutic doses of the drugs did not change the levels of ovarian hydrogen peroxide (H2

APA, Harvard, Vancouver, ISO, and other styles

11

Mishra, Megha, and Anand Mundada. "Simultaneous Estimation and Validation of Artemether and Lumefantrine by UV Spectrophotometry in Tablet." Journal of Drug Delivery and Therapeutics 11, no. 2 (2021): 16–22. http://dx.doi.org/10.22270/jddt.v11i2.4576.

Full text

Abstract:

A UV spectrophotometric method has been developed for the simultaneous determination of Artemether and Lumefantrine. The spectroscopic method for estimation of Artemether and Lumefantrine employed Area under curve method for analysis using Ethanol as solvent. Artemether has absorbance maxima 253.2 nm and Lumefantrine has absorbance maxima 235.2 nm and both these drugs obey Beer's law in concentration range of 4.24 -67.84 μg/ml for Artemether and 4.68 -28.08 μg/ml for Lumefantrine. The recovery studies ascertained the accuracy of the purposed method and the results were validated as per ICH gui

APA, Harvard, Vancouver, ISO, and other styles

12

Bijwar, Rahul, and Harshal Tare. "Solubility and Taste Masked Behaviour of Cyclodextrin Molecular Inclusion Complex of Lumefantrin." INTERNATIONAL JOURNAL OF DRUG DELIVERY TECHNOLOGY 13, no. 04 (2023): 1151–55. http://dx.doi.org/10.25258/ijddt.13.4.04.

Full text

Abstract:

Lumefantrine is an antimalarial drugs used especially for pediatric persons. β-Cyclodextrine is used to improve the taste of lumefantrine by forming complexes with them by the solvent evaporation method, respectively. β-Cyclodextrine prevent the release of drug in the saliva. Lumefantrine is a bitter drug. So masking of bitter taste in the formulation is a prerequisite as it improves the compliance of the patient and product value. Lumefantrine with β-cyclodextrin in a drug-polymer ratio 1:1 gave complete taste masking with a satisfactory result obtained in term of in-vivo and in-vitro evaluat

APA, Harvard, Vancouver, ISO, and other styles

13

Prah, James, Elvis Ofori Ameyaw, Richmond Afoakwah, Patrick Fiawoyife, Ernest Oppong-Danquah, and Johnson Nyarko Boampong. "Quality Assessment of Artemether-Lumefantrine Samples and Artemether Injections Sold in the Cape Coast Metropolis." Journal of Tropical Medicine 2016 (2016): 1–6. http://dx.doi.org/10.1155/2016/8602619.

Full text

Abstract:

Most prescribers and patients in Ghana now opt for the relatively expensive artemether/lumefantrine rather than artesunate-amodiaquine due to undesirable side effects in the treatment of uncomplicated malaria. The study sought to determine the existence of substandard and/or counterfeit artemether-lumefantrine tablets and suspension as well as artemether injection on the market in Cape Coast. Six brands of artemether-lumefantrine tablets, two brands of artemether-lumefantrine suspensions, and two brands of artemether injections were purchased from pharmacies in Cape Coast for the study. The me

APA, Harvard, Vancouver, ISO, and other styles

14

Walimbwa, Stephen I., Mohammed Lamorde, Catriona Waitt, et al. "Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine." Antimicrobial Agents and Chemotherapy 63, no. 2 (2018): e01310-18. http://dx.doi.org/10.1128/aac.01310-18.

Full text

Abstract:

ABSTRACT Across sub-Saharan Africa, patients with HIV on antiretrovirals often get malaria and need cotreatment with artemisinin-containing therapies. We undertook two pharmacokinetic studies in healthy volunteers, using standard adult doses of artemether-lumefantrine or artesunate-amodiaquine given with 50 mg once daily dolutegravir (DTG) to investigate the drug-drug interaction between artemether-lumefantrine or artesunate-amodiaquine and dolutegravir. The dolutegravir/artemether-lumefantrine interaction was evaluated in a two-way crossover study and measured artemether, dihydroartemisinin,

APA, Harvard, Vancouver, ISO, and other styles

15

Mwangi, Victor Irungu, Ruth Mwende Mumo, Daniel Muthui Kiboi, Sabah Ahmed Omar, Zipporah Waithera Ng'ang'a, and Hastings Suba Ozwara. "Methylene blue inhibits lumefantrine-resistant Plasmodium berghei." Journal of Infection in Developing Countries 10, no. 06 (2016): 635–42. http://dx.doi.org/10.3855/jidc.7556.

Full text

Abstract:

Introduction: Chemotherapy still is the most effective way to control malaria, a major public health problem in sub-Saharan Africa. The large-scale use of the combination therapy artemether-lumefantrine for malaria treatment in Africa predisposes lumefantrine to emergence of resistance. There is need to identify drugs that can be used as substitutes to lumefantrine for use in combination therapy. Methylene blue, a synthetic anti-methemoglobinemia drug, has been shown to contain antimalarial properties, making it a candidate for drug repurposing. The present study sought to determine antiplasmo

APA, Harvard, Vancouver, ISO, and other styles

16

Basco, Leonardo K., Jean Bickii, and Pascal Ringwald. "In Vitro Activity of Lumefantrine (Benflumetol) against Clinical Isolates of Plasmodium falciparum in Yaoundé, Cameroon." Antimicrobial Agents and Chemotherapy 42, no. 9 (1998): 2347–51. http://dx.doi.org/10.1128/aac.42.9.2347.

Full text

Abstract:

ABSTRACT The in vitro antimalarial activity of the new Chinese synthetic drug, lumefantrine, also known as benflumetol (a fluorene derivative belonging to the aminoalcohol class), was determined by an isotopic microtest against 61 fresh clinical isolates of Plasmodium falciparum and compared with that of other established antimalarial agents. The geometric mean 50% inhibitory concentration of lumefantrine was 11.9 nmol/liter (95% confidence intervals, 10.4 to 13.6 nmol/liter; range, 3.3 to 25.6 nmol/liter). The in vitro activities of lumefantrine against the chloroquine-sensitive and the chlor

APA, Harvard, Vancouver, ISO, and other styles

17

&NA;. "Artemether/lumefantrine." Reactions Weekly &NA;, no. 1390 (2012): 8. http://dx.doi.org/10.2165/00128415-201213900-00030.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

&NA;. "Artemether/lumefantrine." Reactions Weekly &NA;, no. 1407 (2012): 11–12. http://dx.doi.org/10.2165/00128415-201214070-00037.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

&NA;. "Artemether/lumefantrine." Reactions Weekly &NA;, no. 1321 (2010): 8. http://dx.doi.org/10.2165/00128415-201013210-00016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

&NA;. "Artemether/lumefantrine." Reactions Weekly &NA;, no. 1351 (2011): 12. http://dx.doi.org/10.2165/00128415-201113510-00034.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

&NA;. "Artemether/lumefantrine." Reactions Weekly &NA;, no. 1424 (2012): 13. http://dx.doi.org/10.2165/00128415-201214240-00041.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Echezona, Adaeze Chidiebere, Mumuni Momoh, Paul Achile Akpa, et al. "Effect of molecular interaction on the antiplasmodial efficacy of lumefantrine in amorphous polymethacrylate-urea solid solution." Journal of Drug Delivery and Therapeutics 10, no. 5 (2020): 56–69. http://dx.doi.org/10.22270/jddt.v10i5.4279.

Full text

Abstract:

Malaria, a leading cause of mortality and morbidity in the developing world, with children aged under 5 years, accounts for 61% of all the global malaria deaths. The World Health Organization approved fixed-dose first-line artemisinin-based combination therapy (ACT) – artemether-lumefantrine for effective malaria treatment, is challenged by poor aqueous solubility and inadequate bioavailability leading to treatment failures and emergence of resistant strains. This study focuses on evaluating novel lumefantrine (LF) polymethacrylate-urea solid solutions comprising of a retarding polymer for enh

APA, Harvard, Vancouver, ISO, and other styles

23

Nyunt, Myaing M., Vy K. Nguyen, Richard Kajubi, et al. "Artemether-Lumefantrine Pharmacokinetics and Clinical Response Are Minimally Altered in Pregnant Ugandan Women Treated for Uncomplicated Falciparum Malaria." Antimicrobial Agents and Chemotherapy 60, no. 3 (2015): 1274–82. http://dx.doi.org/10.1128/aac.01605-15.

Full text

Abstract:

Artemether-lumefantrine is a first-line regimen for the treatment of uncomplicated malaria during the second and third trimesters of pregnancy. Previous studies have reported changes in the pharmacokinetics and clinical outcomes following treatment with artemether-lumefantrine in pregnant women compared to nonpregnant adults; however, the results are inconclusive. We conducted a study in rural Uganda to compare the pharmacokinetics of artemether-lumefantrine and the treatment responses between 30 pregnant women and 30 nonpregnant adults with uncomplicatedPlasmodium falciparummalaria. All parti

APA, Harvard, Vancouver, ISO, and other styles

24

Li, Meiqi, Xiaoyu Sang, Xiaohan Zhang, et al. "A Metabolomic and Transcriptomic Study Revealed the Mechanisms of Lumefantrine Inhibition of Toxoplasma gondii." International Journal of Molecular Sciences 24, no. 5 (2023): 4902. http://dx.doi.org/10.3390/ijms24054902.

Full text

Abstract:

Toxoplasma gondii is an obligate protozoon that can infect all warm-blooded animals including humans. T. gondii afflicts one-third of the human population and is a detriment to the health of livestock and wildlife. Thus far, traditional drugs such as pyrimethamine and sulfadiazine used to treat T. gondii infection are inadequate as therapeutics due to relapse, long treatment period, and low efficacy in parasite clearance. Novel, efficacious drugs have not been available. Lumefantrine, as an antimalarial, is effective in killing T. gondii but has no known mechanism of action. We combined metabo

APA, Harvard, Vancouver, ISO, and other styles

25

Kredo, T., K. Mauff, J. S. Van der Walt, et al. "Interaction between Artemether-Lumefantrine and Nevirapine-Based Antiretroviral Therapy in HIV-1-Infected Patients." Antimicrobial Agents and Chemotherapy 55, no. 12 (2011): 5616–23. http://dx.doi.org/10.1128/aac.05265-11.

Full text

Abstract:

ABSTRACTArtemether-lumefantrine and nevirapine-based antiretroviral therapy (ART) are the most commonly recommended first-line treatments for malaria and HIV, respectively, in Africa. Artemether, lumefantrine, and nevirapine are metabolized by the cytochrome P450 3A4 enzyme system, which nevirapine induces, creating potential for important drug interactions. In a parallel-design pharmacokinetic study, concentration-time profiles were obtained in two groups of HIV-infected patients: ART-naïve patients and those stable on nevirapine-based therapy. Both groups received the recommended artemether-

APA, Harvard, Vancouver, ISO, and other styles

26

Pingale, Satish G., and Kiran V. Mangaonkar. "Quantification of Lumefantrine in Human Plasma Using LC-MS/MS and Its Application to a Bioequivalence Study." Journal of Pharmaceutics 2013 (September 23, 2013): 1–8. http://dx.doi.org/10.1155/2013/437697.

Full text

Abstract:

An analytical method based on protein precipitation has been developed and validated for analysis of lumefantrine in human plasma. Artesunate was used as an internal standard for lumefantrine. Inertsil ODS column provided chromatographic separation of analytes followed by detection with mass spectrometry. The method involves simple isocratic chromatographic condition and mass spectrometric detection in the positive ionization mode using an API-3000 system. The total run time was 2.5 minutes. The proposed method has been validated with linear range of 200–20000 ng/mL for lumefantrine. The intra

APA, Harvard, Vancouver, ISO, and other styles

27

Adegbola, Adebanjo J., Julius O. Soyinka, and Oluseye O. Bolaji. "Effect of CYP3A5*3 genotypes on lumefantrine plasma concentrations among malaria-HIV-infected women." Pharmacogenomics 21, no. 18 (2020): 1289–97. http://dx.doi.org/10.2217/pgs-2020-0081.

Full text

Abstract:

Aim: We aimed to assess the effect of a functional polymorphism of CYP3A5 on lumefantrine pharmacokinetics. Patients & methods: Sixty-nine women diagnosed with malaria received standard doses of artemether–lumefantrine. Concentration–time data for lumefantrine and genotyping data were obtained for each participant. Pharmacokinetic-genotype associative relationships were assessed using linear regressions, Mann–Whitney U-test or Kruskal–Wallis statistics. Results: Average age and weight (standard deviation) of the patients were 33 (6.8) years and 59.5 (11.6) kg, respectively. CYP3A5*3 genoty

APA, Harvard, Vancouver, ISO, and other styles

28

Tay, Erin, Tri-Hung Nguyen, Leigh Ford, et al. "Ionic Liquid Forms of the Antimalarial Lumefantrine in Combination with LFCS Type IIIB Lipid-Based Formulations Preferentially Increase Lipid Solubility, In Vitro Solubilization Behavior and In Vivo Exposure." Pharmaceutics 12, no. 1 (2019): 17. http://dx.doi.org/10.3390/pharmaceutics12010017.

Full text

Abstract:

Lipid based formulations (LBFs) are commonly employed to enhance the absorption of highly lipophilic, poorly water-soluble drugs. However, the utility of LBFs can be limited by low drug solubility in the formulation. Isolation of ionizable drugs as low melting, lipophilic salts or ionic liquids (ILs) provides one means to enhance drug solubility in LBFs. However, whether different ILs benefit from formulation in different LBFs is largely unknown. In the current studies, lumefantrine was isolated as a number of different lipophilic salt/ionic liquid forms and performance was assessed after form

APA, Harvard, Vancouver, ISO, and other styles

29

Ma, Yufan, Tingli Lu, Wen Zhao, et al. "Enhanced Antimalarial Activity by a Novel Artemether-Lumefantrine Lipid Emulsion for Parenteral Administration." Antimicrobial Agents and Chemotherapy 58, no. 10 (2014): 5658–65. http://dx.doi.org/10.1128/aac.01428-13.

Full text

Abstract:

ABSTRACTArtemether and lumefantrine (also known as benflumetol) are difficult to formulate for parenteral administration because of their low aqueous solubility. Cremophor EL as an emulsion excipient has been shown to cause serious side effects. This study reports a method of preparation and the therapeutic efficacies of novel lipid emulsion (LE) delivery systems with artemether, lumefantrine, or artemether in combination with lumefantrine, for parenteral administration. Their physical and chemical stabilities were also evaluated. Furthermore, thein vivoantimalarial activities of the lipid emu

APA, Harvard, Vancouver, ISO, and other styles

30

Ebubechukwu Favour Chibzoom-Pius, Chibueze Peter Ihekwereme, Adanna Perpetua Ikebudu, and Amara Naomi Ulasi. "Evaluation of the interaction between the ethanol pulp extract of Chrysophyllum albidum and Artemether/ Lumefantrine." International Journal of Science and Research Archive 14, no. 1 (2025): 679–86. https://doi.org/10.30574/ijsra.2025.14.1.0045.

Full text

Abstract:

Objective: Though Chrysophyllum albidum has antimalarial and antioxidant property, it is commonly consumed as a fruit in the South East Nigeria. There could be possible pharmacodynamics and pharmacokinetics interaction if the fruit is consumed while on malaria treatment with artemether-lumefantrine. The study was designed to investigate the possible enhancement of the antimalarial potency as well as possible herb-drug interaction resulting from concurrent administration of artemeter-lumefantrine and Chrysophyllum albidum. Materials and methods: Combinations of artemeter-lumefantrine and Chryso

APA, Harvard, Vancouver, ISO, and other styles

31

Wong, Rina P. M., Sam Salman, Kenneth F. Ilett, Peter M. Siba, Ivo Mueller, and Timothy M. E. Davis. "Desbutyl-Lumefantrine Is a Metabolite of Lumefantrine with PotentIn VitroAntimalarial Activity That May Influence Artemether-Lumefantrine Treatment Outcome." Antimicrobial Agents and Chemotherapy 55, no. 3 (2011): 1194–98. http://dx.doi.org/10.1128/aac.01312-10.

Full text

Abstract:

ABSTRACTDesbutyl-lumefantrine (DBL) is a metabolite of lumefantrine. Preliminary data fromPlasmodium falciparumfield isolates show greater antimalarial potency than, and synergy with, the parent compound and synergy with artemisinin. In the present study, thein vitroactivity and interactions of DBL were assessed from tritium-labeled hypoxanthine uptake in cultures of the laboratory-adapted strains 3D7 (chloroquine sensitive) and W2mef (chloroquine resistant). The geometric mean 50% inhibitory concentrations (IC50s) for DBL against 3D7 and W2mef were 9.0 nM (95% confidence interval, 5.7 to 14.4

APA, Harvard, Vancouver, ISO, and other styles

32

Tumwebaze, Patrick, Melissa D. Conrad, Andrew Walakira, et al. "Impact of Antimalarial Treatment and Chemoprevention on the Drug Sensitivity of Malaria Parasites Isolated from Ugandan Children." Antimicrobial Agents and Chemotherapy 59, no. 6 (2015): 3018–30. http://dx.doi.org/10.1128/aac.05141-14.

Full text

Abstract:

ABSTRACTChanging treatment practices may be selecting for changes in the drug sensitivity of malaria parasites. We characterizedex vivodrug sensitivity and parasite polymorphisms associated with sensitivity in 459Plasmodium falciparumsamples obtained from subjects enrolled in two clinical trials in Tororo, Uganda, from 2010 to 2013. Sensitivities to chloroquine and monodesethylamodiaquine varied widely; sensitivities to quinine, dihydroartemisinin, lumefantrine, and piperaquine were generally good. Associations betweenex vivodrug sensitivity and parasite polymorphisms included decreased chloro

APA, Harvard, Vancouver, ISO, and other styles

33

Karl, Stephan, Moses Laman, Brioni R. Moore, et al. "Gametocyte Clearance Kinetics Determined by Quantitative Magnetic Fractionation in Melanesian Children with Uncomplicated Malaria Treated with Artemisinin Combination Therapy." Antimicrobial Agents and Chemotherapy 59, no. 8 (2015): 4489–96. http://dx.doi.org/10.1128/aac.00136-15.

Full text

Abstract:

ABSTRACTQuantitative magnetic fractionation and a published mathematical model were used to characterize between-treatment differences in gametocyte density and prevalence in 70 Papua New Guinean children with uncomplicatedPlasmodium falciparumand/orPlasmodium vivaxmalaria randomized to one of two artemisinin combination therapies (artemether-lumefantrine or artemisinin-naphthoquine) in an intervention trial. There was an initial rise in peripheralP. falciparumgametocyte density with both treatments, but it was more pronounced in the artemisinin-naphthoquine group. Model-derived estimates of t

APA, Harvard, Vancouver, ISO, and other styles

34

Tarning, Joel, Rose McGready, Niklas Lindegardh, et al. "Population Pharmacokinetics of Lumefantrine in Pregnant Women Treated with Artemether-Lumefantrine for Uncomplicated Plasmodium falciparum Malaria." Antimicrobial Agents and Chemotherapy 53, no. 9 (2009): 3837–46. http://dx.doi.org/10.1128/aac.00195-09.

Full text

Abstract:

ABSTRACT Artemether-lumefantrine has become one of the most widely used antimalarial drugs in the world. The objective of this study was to determine the population pharmacokinetic properties of lumefantrine in pregnant women with uncomplicated multidrug-resistant Plasmodium falciparum malaria on the northwestern border of Thailand. Burmese and Karen women (n = 103) with P. falciparum malaria and in the second and third trimesters of pregnancy were treated with artemether-lumefantrine (80/480 mg) twice daily for 3 days. All patients provided five capillary plasma samples for drug quantificatio

APA, Harvard, Vancouver, ISO, and other styles

35

Ezzet, F., M. van Vugt, F. Nosten, S. Looareesuwan, and N. J. White. "Pharmacokinetics and Pharmacodynamics of Lumefantrine (Benflumetol) in Acute Falciparum Malaria." Antimicrobial Agents and Chemotherapy 44, no. 3 (2000): 697–704. http://dx.doi.org/10.1128/aac.44.3.697-704.2000.

Full text

Abstract:

ABSTRACT The objective of this study was to conduct a prospective population pharmacokinetic and pharmacodynamic evaluation of lumefantrine during blinded comparisons of artemether-lumefantrine treatment regimens in uncomplicated multidrug-resistant falciparum malaria. Three combination regimens containing an average adult lumefantrine dose of 1,920 mg over 3 days (four doses) (regimen A) or 2,780 mg over 3 or 5 days (six doses) (regimen B or C, respectively) were given to 266 Thai patients. Detailed observations were obtained for 51 hospitalized adults, and sparse data were collected for 215

APA, Harvard, Vancouver, ISO, and other styles

36

&NA;. "Artemether/lumefantrine/artesunate." Reactions Weekly &NA;, no. 1422 (2012): 10. http://dx.doi.org/10.2165/00128415-201214220-00030.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Roth, Johanna M., Patrick Sawa, Nicodemus Makio, et al. "Pyronaridine–artesunate and artemether–lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a randomized controlled non-inferiority trial." Malaria Journal 17, no. 1 (2018): 199. https://doi.org/10.1186/s12936-018-2340-3.

Full text

Abstract:

<strong>Background: </strong>Pyronaridine–artesunate is a novel artemisinin-based combination therapy. The efficacy and safety of pyronaridine–artesunate were compared with artemether–lumefantrine for the treatment of uncomplicated <i>Plasmodium falciparum</i> malaria in children.<strong>Methods: </strong>This phase III open-label randomized controlled non-inferiority trial was conducted in Western Kenya. Children aged 6 months to ≤ 12 years with a bodyweight > 5 kg and microscopically confirmed <i>P. falciparum</i> malaria were randomly assigned in a 1:1 ratio to orally receive pyronaridin

APA, Harvard, Vancouver, ISO, and other styles

38

Solomon, Opoku, and Nyanor Isaac. "In Vitro Inhibition of Staphylococcus aureus subsp. aureus (ATCC® 6538™) by Artemether-Lumefantrine Tablets: A Comparative Study of Three Dosage Strengths." Open Microbiology Journal 12, no. 1 (2018): 397–403. http://dx.doi.org/10.2174/1874285801812010397.

Full text

Abstract:

Purpose: Antibiotics are progressively failing in the fight against infections due to S. aureus because the bacterium has an outstanding ability to acquire multi-antibiotic resistance and become resistant to most antibiotics. Multi-drug resistant S. aureus poses a major threat to the foundation upon which standard antibacterial chemotherapy stands, hence the need to consider non-antibiotic solutions to manage invasive bacterial infections. This study investigated the inhibitory activities of three dosage strengths of artemether-lumefantrine tablets against Staphylococcus aureus subsp. aureus (

APA, Harvard, Vancouver, ISO, and other styles

39

De la Hoz Restrepo, Fernando, Alexandra Porras Ramírez, Alejandro Rico Mendoza, Freddy Córdoba, and Diana Patricia Rojas. "Artesunate + amodiaquine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in the Colombian Pacific region: a noninferiority trial." Revista da Sociedade Brasileira de Medicina Tropical 45, no. 6 (2012): 732–38. http://dx.doi.org/10.1590/s0037-86822012000600015.

Full text

Abstract:

INTRODUCTION: In Colombia, there are no published studies for the treatment of uncomplicated Plasmodium falciparum malaria comparing artemisinin combination therapies. Hence, it is intended to demonstrate the non-inferior efficacy/safety profiles of artesunate + amodiaquine versus artemether-lumefantrine treatments. METHODS: A randomized, controlled, open-label, noninferiority (Δ≤5%) clinical trial was performed in adults with uncomplicated P. falciparum malaria using the 28‑day World Health Organization validated design/definitions. Patients were randomized 1:1 to either oral artesunate + amo

APA, Harvard, Vancouver, ISO, and other styles

40

Venkata Rao, Payyavula, and Rambabu C. "VALIDATED REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC METHOD FOR THE SIMULTANEOUS DETERMINATION OF ARTEMETHER AND LUMEFANTRINE IN FIXED COMBINED DOSAGE FORM." Asian Journal of Pharmaceutical and Clinical Research 10, no. 3 (2017): 159. http://dx.doi.org/10.22159/ajpcr.2017.v10i3.15930.

Full text

Abstract:

ABSTRACTObjective: The present aim is to develop simple, precise, and accurate reverse phase high performance liquid chromatographic method (RP-HPLC) forthe simultaneous assay of artemether and lumefantrine in fixed combined dosage form.Methods: The chromatographic study was carried out on Hypersil C18 column (250×4.6 mm, 5 μ) with mobile phase containing a mixture of KH2PO4buffer (pH-3.5) and acetonitrile in the ratio of 45:55% v/v at a flow rate of 1.0 ml/minute with ultraviolet detection at 218 nm in ambient columntemperature.Results: Using the optimized chromatographic conditions artemethe

APA, Harvard, Vancouver, ISO, and other styles

41

Tarning, Joel, Frank Kloprogge, Mehul Dhorda, et al. "Pharmacokinetic Properties of Artemether, Dihydroartemisinin, Lumefantrine, and Quinine in Pregnant Women with Uncomplicated Plasmodium falciparum Malaria in Uganda." Antimicrobial Agents and Chemotherapy 57, no. 10 (2013): 5096–103. http://dx.doi.org/10.1128/aac.00683-13.

Full text

Abstract:

ABSTRACTPregnancy alters the pharmacokinetic properties of many drugs used in the treatment of malaria, usually resulting in lower drug exposures. This increases the risks of treatment failure, adverse outcomes for the fetus, and the development of resistance. The pharmacokinetic properties of artemether and its principal metabolite dihydroartemisinin (n= 21), quinine (n= 21), and lumefantrine (n= 26) in pregnant Ugandan women were studied. Lumefantrine pharmacokinetics in a nonpregnant control group (n= 17) were also studied. Frequently sampled patient data were evaluated with noncompartmenta

APA, Harvard, Vancouver, ISO, and other styles

42

Byakika-Kibwika, Pauline, Mohammed Lamorde, Harriet Mayanja-Kizza, Saye Khoo, Concepta Merry, and Jean-Pierre Van geertruyden. "Artemether-Lumefantrine Combination Therapy for Treatment of Uncomplicated Malaria: The Potential for Complex Interactions with Antiretroviral Drugs in HIV-Infected Individuals." Malaria Research and Treatment 2011 (April 6, 2011): 1–5. http://dx.doi.org/10.4061/2011/703730.

Full text

Abstract:

Treatment of malaria in HIV-infected individuals receiving antiretroviral therapy (ART) poses significant challenges. Artemether-lumefantrine (AL) is one of the artemisisnin-based combination therapies recommended for treatment of malaria. The drug combination is highly efficacious against sensitive and multidrug resistant falciparum malaria. Both artemether and lumefantrine are metabolized by hepatic cytochrome P450 (CYP450) enzymes which metabolize the protease inhibitors (PIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs) used for HIV treatment. Coadministration of NNRTIs and

APA, Harvard, Vancouver, ISO, and other styles

43

Ndounga, Mathieu, Rachida Tahar, Prisca N. Casimiro, Dieudonné Loumouamou, and Leonardo K. Basco. "Clinical Efficacy of Artemether-Lumefantrine in Congolese Children with Acute Uncomplicated Falciparum Malaria in Brazzaville." Malaria Research and Treatment 2012 (December 17, 2012): 1–5. http://dx.doi.org/10.1155/2012/749479.

Full text

Abstract:

The Republic of the Congo adopted artemisinin-based combination therapies (ACTs) in 2006: artesunate-amodiaquine and artemether-lumefantrine as the first-line and second-line drugs, respectively. The baseline efficacy of artemether-lumefantrine was evaluated between March and July 2006 in Brazzaville, the capital city of Congo. Seventy-seven children aged between 6 months and 10 years were enrolled in a nonrandomized study. The children were treated under supervision with 6 doses of artemether-lumefantrine and followed up for 28 days in accordance with the 2003 World Health Organization guidel

APA, Harvard, Vancouver, ISO, and other styles

44

Noudjiegbe, Adrien N., Femi N. Alikekere, Henri Tchehouenou, et al. "A Phase II Pilot Trial to Evaluate CoBaT-Y017 Safety and Efficacy against Uncomplicated Falciparum Malaria versus Artemether-Lumefantrine in Benin Subjects." Evidence-Based Complementary and Alternative Medicine 2020 (February 17, 2020): 1–9. http://dx.doi.org/10.1155/2020/8715021.

Full text

Abstract:

Background. Considering the promising results of Phase I clinical trials with herbal medicine CoBaT-Y017, a Phase II study was conducted with Plasmodium falciparum malaria-infected patients, for efficacy and safety evaluation of CoBaT-Y017 compared with Artemether-Lumefantrine used as a positive control. Methods. A single-blind randomized trial was conducted on 25 eligible males aged 18–40 years randomly assigned to two treatment groups: CoBaT-Y017 or Artemether-Lumefantrine. The first group received 35 ml of CoBaT-Y017 in 1.5 L mineral water administered daily for four consecutive days; the s

APA, Harvard, Vancouver, ISO, and other styles

45

Dahlström, Sabina, Agnès Aubouy, Oumou Maïga-Ascofaré, et al. "Plasmodium falciparum Polymorphisms Associated withEx VivoDrug Susceptibility and Clinical Effectiveness of Artemisinin-Based Combination Therapies in Benin." Antimicrobial Agents and Chemotherapy 58, no. 1 (2013): 1–10. http://dx.doi.org/10.1128/aac.01790-12.

Full text

Abstract:

ABSTRACTArtemisinin-based combination therapies (ACTs) are the main option to treat malaria, and their efficacy and susceptibility must be closely monitored to avoid resistance. We assessed the association ofPlasmodium falciparumpolymorphisms andex vivodrug susceptibility with clinical effectiveness. Patients enrolled in an effectiveness trial comparing artemether-lumefantrine (n= 96), fixed-dose artesunate-amodiaquine (n= 96), and sulfadoxine-pyrimethamine (n= 48) for the treatment of uncomplicated malaria 2007 in Benin were assessed.pfcrt,pfmdr1,pfmrp1,pfdhfr, andpfdhpspolymorphisms were ana

APA, Harvard, Vancouver, ISO, and other styles

46

ARISE, Rotimi Olusanya, Adedibu Clement TELLA, Oluyinka A. IYIOLA, Oluwakemi Mary AYENI, Samuel Tobi FAROHUNBI, and Abeeb Abiodun YEKEEN. "Solvent-less Synthesis, Antimalarial and Toxicity Evaluation of Lumefantrine-Copper Complex in Swiss Mice." Notulae Scientia Biologicae 8, no. 3 (2016): 292–300. http://dx.doi.org/10.15835/nsb839856.

Full text

Abstract:

The antimalarial efficacy and safety of mechanically induced solventlessly synthesized lumefantrine-copper complex were investigated in experimental mice. Parasite level in Plasmodium berghei-infected mice treated with lumefantrine - copper complex (LCC) significantly declined (p < 0.05) at day 3 and was comparable with that of chloroquine-treated mice. LCC attained a percentage chemo-suppression which was significantly higher than those of pure lumefantrine and comparable with chloroquine. Pure lumefantrine attained a clearance of 88.52%, chloroquine was 91.95%, while LCC was 95.10%. Admin

APA, Harvard, Vancouver, ISO, and other styles

47

Achile Akpa, Paul, Joseph Abuchi Ugwuoke, Anthony Amaechi Attama, et al. "Improved antimalarial activity of caprol-based nanostructured lipid carriers encapsulating artemether-lumefantrine for oral administration." African Health Sciences 20, no. 4 (2020): 1679–97. http://dx.doi.org/10.4314/ahs.v20i4.20.

Full text

Abstract:

Background: Artemether and lumefantrine display low aqueous solubility leading to poor release profile; hence the need for the use of lipid-based systems to improve their oral bioavailability so as to improve their therapeutic efficacy. Aim and objective: The objective of this work was to utilize potentials of nanostructured lipid carriers (NLCs) for im- provement of the oral bioavailability of artemether and lumefantrine combination and to evaluate its efficacy in the treat- ment of malaria. This study reports a method of formulation, characterization and evaluation of the therapeutic e

APA, Harvard, Vancouver, ISO, and other styles

48

Muti’ah, Roihatul. "PENYAKIT MALARIA DAN MEKANISME KERJA OBAT-OBAT ANTIMALARIA." ALCHEMY, May 14, 2013. http://dx.doi.org/10.18860/al.v0i0.2293.

Full text

Abstract:

<p>Malariais one of theinfectious diseaseis stillaproblem ofthe world withhigh mortality. Therapeutic purpose of uncomplicated malariais to eliminateplasmodiumcause infection to preventinfectionseverity, complications andbreak the chain oftransmission. While the purpose therapyof severemalaria is to prevent mortality.Recommendedtherapy of malaria isa combination of twoormore antimalarial drugsthat mechanisms actionkillsmalarialparasitesin thebloodand theamount of each drugworks ondifferent receptors. The use ofa combination ofseveralantimalarial drugshas becomea necessityforprevention of

APA, Harvard, Vancouver, ISO, and other styles

49

Shanmugasundaram, P., S. Harshini, and G. Nithish Kumar. "A systematic review of lumefantrine." Annals of Phytomedicine An International Journal 12, no. 2 (2023). http://dx.doi.org/10.54085/ap.2023.12.2.31.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Adegbola, Adebanjo, Rana Abutaima, Adeniyi Olagunju, et al. "Effect of Pregnancy on the Pharmacokinetic Interaction between Efavirenz and Lumefantrine in HIV-Malaria Coinfection." Antimicrobial Agents and Chemotherapy 62, no. 10 (2018). http://dx.doi.org/10.1128/aac.01252-18.

Full text

Abstract:

ABSTRACT Artemether-lumefantrine is often coadministered with efavirenz-based antiretroviral therapy for malaria treatment in HIV-infected women during pregnancy. Previous studies showed changes in lumefantrine pharmacokinetics due to interaction with efavirenz in nonpregnant adults. The influence of pregnancy on this interaction has not been reported. This pharmacokinetic study involved 35 pregnant and 34 nonpregnant HIV-malaria-coinfected women receiving efavirenz-based antiretroviral therapy and was conducted in four health facilities in Nigeria. Participants received a 3-day standard regim

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!